Chembio Awarded $750,000 Cooperative Research Agreement

Chembio Awarded $750,000 Cooperative Research Agreement

MEDFORD, N.Y., May 23, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI) a leader in point-of-care ("POC") diagnostic tests for
infectious diseases, announced today that it has been awarded a cooperative
research agreement with aU.S. government agency for up to $750,000 for an
eight month development project. The project is to develop rapid POC
diagnostic tests for five infectious diseases associated with febrile illness
and to multiplex them into one assay.The project also contemplates that the
test would be optimized for use with a mobile reader that incorporates cell
phone technology to enable the results to be recorded, transmitted and
monitored remotely via a cloud system, in real-time.

Javan Esfandiari, Chembio's Senior Vice President of Research & Development
and the inventor of DPP^®, commented, "We are pleased to be awarded this
research project to develop a complex multiplex assay as it builds on our
strength in developing multiplex products using our proprietary DPP^®
technology. Our DPP^® technology, combined with the mobile reader being used
in the project, will enable real time data collection and monitoring
capabilities. As these infectious diseases can all exhibit similar clinical
symptoms, a rapid multiplex test that could distinguish them would be very
useful, particularly in field conditions, so that correct diagnosis and
treatment could be provided on a timely basis."

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP®) technology, which has significant
advantages over lateral-flow technologies. This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U.S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485. For more
information, please visit: www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended.Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management.Such
statements are estimates only, as the Company has not completed the
preparation of its financial statements for those periods, nor has its auditor
completed a review or audit of those results.Actual revenue may differ
materially from those anticipated in this press release.Such statements
reflect management's current views, are based on certain assumptions and
involve risks and uncertainties.Actual results, events, or performance may
differ materially from the above forward-looking statements due to a number of
important factors, and will be dependent upon a variety of factors, including,
but not limited to Chembio's ability to obtain additional financing, to obtain
regulatory approvals in a timely manner and the demand for Chembio's
products.Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur after
the date hereof or to reflect any change in Chembio's expectations with regard
to these forward-looking statements or the occurrence of unanticipated
events.Factors that may impact Chembio's success are more fully disclosed in
Chembio's most recent public filings with the U.S. Securities and Exchange
Commission.

CONTACT: Chembio Diagnostics
         Susan Norcott
         (631) 924-1135, ext. 125
         snorcott@chembio.com
        
         LHA
         Anne Marie Fields
         (212) 838-3777
         AFields@lhai.com
         @LHA_IR_PR
 
Press spacebar to pause and continue. Press esc to stop.